BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Breaking News: BioWorld 2025 Year in ReviewBreaking News: BioWorld MedTech 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld

BioWorld
BioWorld RSS Feed RSS

Illustration of tumor on kidney

FDA accepts Telix BLA for kidney cancer imaging agent

Feb. 27, 2025
By Tamra Sami
After a second round, the U.S. FDA has accepted for review radiopharmaceutical company Telix Pharmaceuticals Ltd.’s BLA for its kidney cancer PET imaging agent, TLX250-CDx (Zircaix, 89Zr-DFO-girentuximab), granting it a priority review with a PDUFA date of Aug. 27, 2025.
Read More

Regulatory actions for Feb. 27, 2025

Feb. 27, 2025
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arcutis, Ardelyx, Auron, BMS, Celltrion, Gilead, Glaukos, Indivior, Innovent, Insmed, Invivyd, Opus, Porosome, Pyxis, Regeneron, Takeda, Telix, Teva.
Read More

In the clinic for Feb. 27, 2025

Feb. 27, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alligator, Arialys, Astrazeneca, Biocity, Candel, Cognition, Cstone, Emalex, Imunon, Innocare, Madrigal, Mediwound, Novita, PDS.
Read More

Other news to note for Feb. 27, 2025

Feb. 27, 2025
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allogene, Enodia, Eli Lilly, Foresight, Idorsia, Nxera, Pfizer, Viatris.
Read More

Financings for Feb. 27, 2025

Feb. 27, 2025
Biopharmas raising money in public or private financings, including: Biomx, Enveda, Ignota Labs, Moleculin, Renovaro, Sanofi.
Read More

Appointments and advancements for Feb. 27, 2025

Feb. 27, 2025
New hires and promotions in the biopharma industry, including: Cancervax, Wugen.
Read More

Biocity’s SC-0062 hits phase II endpoints in diabetic kidney disease

Feb. 26, 2025
By Tamra Sami
Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II diabetic kidney disease cohort. Conducted at 40 sites across China, the 2-Succeed phase II trial is designed to evaluate the efficacy and safety of SC-0062 in patients with chronic kidney disease with proteinuria.
Read More
Biocom AI panel

Biocom 2025: The quickly evolving AI landscape

Feb. 26, 2025
By Brian Orelli
A panel at Biocom California’s 15th Annual Global Life Science Partnering & Investor Conference covered the emerging use of artificial intelligence (AI) to discover and develop drugs. “We’re in a very different place than we were five years ago, or even three years ago, even two years ago, from our ability to harness AI to make advances,” Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics Inc., told the audience, adding that the development is actually accelerating.
Read More
Alfred Bowie, chief financial officer, Eikon

Eikon tops the year’s VC rounds as it enters a phase III in cancer

Feb. 26, 2025
By Lee Landenberger
With the closing of its $350.7 million series D, Eikon Therapeutics Inc. has notched two financial high marks for the still young year. The funding is the biggest venture capital round of 2025 and it’s also the first series D.
Read More
Gold wireframe handshake

Harbour Biomed newco HBM Alpha pens $395M hyperplasia drug deal

Feb. 26, 2025
By Marian (YoonJee) Chu
HBM Alpha Therapeutics Inc. signed a potential $395 million licensing deal Feb. 26 with an unnamed “business partner” for its endocrine asset, HAT-001, adding another contender to the congenital adrenal hyperplasia space.
Read More
Previous 1 2 … 274 275 276 277 278 279 280 281 282 … 8959 8960 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 30, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing